Skip to content

Normothermic oxygenated kidney perfusion in elderly donors

Normothermic oxygenated kidney perfusion in elderly donors - POSEIDON study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON44614
Enrollment
10
Registered
2017-11-29
Start date
2018-02-04
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney failure renal failure

Interventions

At the Erasmus MC operating room complex, the donor kidney(s) will be unpacked under sterile conditions, benched to assess acceptability for transplantation. During the benching, 2 pre-defined biops

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Recipient age * 65 yr - Listed for renal transplantation due to end stage renal disease on the ET list

Exclusion criteria

Exclusion criteria: - Donor kidney which is unsuitable for transplantation

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be the logistic challenges in including patients and treatment with normothermic ex vivo kidney perfusion (e.g. failed perfusion procedures, renal artery or vein thrombosis, participation rate).

Secondary

MeasureTime frame
1. Renal histology at start and end of normothermic perfusion 2. Measured glomerular filtration rate * the best surrogate of graft function * (first 4 weeks, 3-months post-transplant), which is considered to be a predictor of long term kidney graft survival as well. 3. 3-month graft (censored and uncensored for recipient death) and patient survival 4. Incidence and severity of delayed graft function defined as the need for dialysis within the first 7 days after kidney transplantation and preceding the return of kidney function. * 5. Incidence of primary non-function (PNF) defined as the permanent lack of function of the graft from time of transplantation until months post-transplant. This endpoint is determined post-hoc at 3 months post-transplant. * 6. Biopsy proven acute rejection within 3 months post-transplant.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)